Equity · Healthcare
NTLA
NASDAQIntellia Therapeutics (NTLA)
The line runs 12 USD on 10 August through 12.82 USD on 29 October, on a scale from 10 to 14. Days the market did not trade hold the previous close, flat.
- Market cap
- 1.8B USD
- Revenue, year to Dec 2025
- 67.7M USD
- EPS, diluted, year to Dec 2025
- −3.81 USD
- 52-week range
- 8.04 USD – 26 USD
- Avg volume
- 323.6K
as of Oct 29, 2026
Have Intellia Therapeutics (NTLA) insiders bought or sold shares recently?
In the 90 days to 9 Nov 2026, Intellia Therapeutics insiders reported 4 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 5 Jan 2026.
Form 4, 90 days to 9 Nov 2026, newest reported trade 2 Nov 2026
Buys 0Sells 4Net sold $418KOther filings 1
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 02 Nov 2026 | LEONARD JOHN MPresident and CEO | Sell | 9,000 | 108K USD |
| 02 Oct 2026 | Dube Michael PVP, Chief Accounting Officer | Sell | 1,864 | 23K USD |
| 21 Aug 2026 | LEONARD JOHN MPresident and CEO | Sell | 2,785 | 36K USD |
| 20 Aug 2026 | LEONARD JOHN MPresident and CEO | Sell | 19,890 | 251K USD |
| Sold | 4 open-market sales | 33,539 | $418K |
1 other filing in the window: a grant, exercise, tax withholding or transfer, not a trade
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 26 Oct 2026 | Marantz Jing L.EVP, Chief Medical Officer | Award | 199,822 |
Which funds hold Intellia Therapeutics (NTLA)?
11 of the 45 institutional funds we track reported a Intellia Therapeutics position for the quarter ended 30 Jun 2026 — a combined 553.5M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| ARK Investment Management | Held (±25%) | 16,875,684 | 285.5M USD | +16.3% |
| D. E. Shaw & Co. | Held (±25%) | 6,443,323 | 109.0M USD | +12.5% |
| Two Sigma Investments | Held (±25%) | 5,235,348 | 88.6M USD | +11.3% |
| Renaissance Technologies | New position | 1,400,004 | 23.7M USD | |
| Baker Bros. Advisors | New position | 930,232 | 15.7M USD | |
| AQR Capital Management | Held (±25%) | 492,954 | 8.3M USD | −21.8% |
| Millennium Management | Added | 491,226 | 8.3M USD | +596.2% |
| Point72 Asset Management | Added | 398,463 | 6.7M USD | +47.6% |
| Citadel Advisors | Trimmed | 164,712 | 2.8M USD | −64.1% |
| Marshall Wace | Held (±25%) | 164,078 | 2.8M USD | +19.4% |
Showing the 10 largest of 11 reported positions. The figures above count all of them.
Have members of Congress traded Intellia Therapeutics (NTLA)?
The most recent congressional trade disclosed in Intellia Therapeutics is a sale by Donald S. Beyer, Jr. (house, VA), dated 28 Feb 2022.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 28 Feb 2022 | Donald S. Beyer, Jr.house · Democrat–VA | Sale | 15K USD–50K USD | 3 days |
| 29 Oct 2021 | Donald S. Beyer, Jr.house · Democrat–VA | Sale | 1K USD–15K USD | 1 day |
| 20 Sep 2021 | Donald S. Beyer, Jr.house · Democrat–VA | Sale | 1K USD–15K USD | 11 days |
| 18 Nov 2020 | Donald S. Beyer, Jr.house · Democrat–VA | Purchase | 1K USD–15K USD | 13 days |
| 26 Aug 2020 | Donald S. Beyer, Jr.house · Democrat–VA | Sale | 1K USD–15K USD | 11 days |
| 10 Jul 2020 | Donald S. Beyer, Jr.house · Democrat–VA | Purchase | 1K USD–15K USD | 30 days |
| 14 Jan 2020 | Donald S. Beyer, Jr.house · Democrat–VA | Purchase | 1K USD–15K USD | 39 days |
| 09 Dec 2019 | Donald S. Beyer, Jr.house · Democrat–VA | Purchase | 1K USD–15K USD | 5 days |
What has been filed or recorded for Intellia Therapeutics (NTLA)?
The filings we hold for Intellia Therapeutics, newest first: 4 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 13 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 13 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,130 shares | 14K USD notional · 0.001% of shares out |
| 07 Oct 2026 | Fails to deliver | Shares failed to deliver | 91,332 shares | 1.1M USD notional · 0.065% of shares out |
| 06 Oct 2026 | Fails to deliver | Shares failed to deliver | 27,293 shares | 348K USD notional · 0.019% of shares out |
| 30 Sep 2026 | Fails to deliver | Shares failed to deliver | 399,250 shares | 4.8M USD notional · 0.285% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.91 USD | Revenue $7M |
| 30 Sep 2026 | Financials | Total assets | 902.6M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 613.1M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.80 USD | Revenue $8M |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.81 USD | Revenue $15M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −3.81 USD | Revenue $68M |
| 31 Dec 2025 | Financials | Revenue | 67.7M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −412.7M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −3.81 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.92 USD | Revenue $14M |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.98 USD | Revenue $14M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −1.10 USD | Revenue $17M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −5.25 USD | Revenue $58M |
Intellia Therapeutics (NTLA): frequently asked questions
What did Intellia Therapeutics shares close at?
Intellia Therapeutics closed at 12.82 USD on 29 Oct 2026, down 1.38% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Intellia Therapeutics’ market cap?
Intellia Therapeutics is worth 1.8B USD by market value as of 29 Oct 2026, which is the share price times the shares on issue from its SEC filings.
What is Intellia Therapeutics’ revenue?
Intellia Therapeutics reported revenue of 67.7M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Intellia Therapeutics insiders bought or sold shares recently?
In the 90 days to 9 Nov 2026, Intellia Therapeutics insiders reported 4 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 5 Jan 2026. A further 1 filing was a grant, award, gift or exercise rather than an open-market trade. See Insiders
Which funds own Intellia Therapeutics?
11 of the 45 funds we track reported a Intellia Therapeutics position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were ARK Investment Management, D. E. Shaw & Co. and Two Sigma Investments. See Funds
Have members of Congress traded Intellia Therapeutics?
Yes. 8 trades in Intellia Therapeutics appear in the congressional disclosures we hold; the latest is a sale by Donald S. Beyer, Jr. (House, VA) dated 28 Feb 2022, filed 3 Mar 2022. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Intellia Therapeutics last report earnings?
Intellia Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.91 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings